These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19084450)

  • 1. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.
    Recker RR; Ste-Marie LG; Langdahl B; Masanauskaite D; Ethgen D; Delmas PD
    J Clin Densitom; 2009; 12(1):71-6. PubMed ID: 19084450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
    Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
    Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
    Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.
    Recker RR; Ste-Marie LG; Langdahl B; Czerwinski E; Bonvoisin B; Masanauskaite D; Rowell L; Felsenberg D
    Bone; 2010 Mar; 46(3):660-5. PubMed ID: 19909829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
    J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
    Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
    Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
    Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
    Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.
    Chapurlat RD; Laroche M; Thomas T; Rouanet S; Delmas PD; de Vernejoul MC
    Osteoporos Int; 2013 Jan; 24(1):311-20. PubMed ID: 22402673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
    Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
    Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
    Schafer AL; Burghardt AJ; Sellmeyer DE; Palermo L; Shoback DM; Majumdar S; Black DM
    Osteoporos Int; 2013 Oct; 24(10):2591-601. PubMed ID: 23589163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of vertebral fracture reflects deterioration of bone microarchitecture.
    Genant HK; Delmas PD; Chen P; Jiang Y; Eriksen EF; Dalsky GP; Marcus R; San Martin J
    Osteoporos Int; 2007 Jan; 18(1):69-76. PubMed ID: 17028792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
    Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D
    Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
    Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
    Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
    Sambrook P; Cranney A; Adachi JD
    Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.